Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Botswana | 102 | 2023 | 1034 | 8.610 |
Why?
|
Pregnancy Complications, Infectious | 50 | 2023 | 2028 | 7.510 |
Why?
|
HIV Infections | 130 | 2023 | 16764 | 7.330 |
Why?
|
Infectious Disease Transmission, Vertical | 43 | 2023 | 1331 | 6.200 |
Why?
|
Premature Birth | 18 | 2023 | 1702 | 4.300 |
Why?
|
Anti-HIV Agents | 44 | 2023 | 4320 | 3.980 |
Why?
|
Stillbirth | 14 | 2023 | 346 | 3.460 |
Why?
|
Anti-Retroviral Agents | 24 | 2023 | 1734 | 3.420 |
Why?
|
HIV-1 | 50 | 2023 | 6931 | 3.350 |
Why?
|
Antiretroviral Therapy, Highly Active | 24 | 2020 | 1896 | 3.220 |
Why?
|
Breast Feeding | 24 | 2023 | 1334 | 2.750 |
Why?
|
Heterocyclic Compounds, 3-Ring | 5 | 2021 | 217 | 2.540 |
Why?
|
Pregnancy Outcome | 19 | 2023 | 2789 | 2.370 |
Why?
|
Pregnancy | 80 | 2023 | 29002 | 1.970 |
Why?
|
Infant Mortality | 11 | 2019 | 749 | 1.700 |
Why?
|
Infant, Newborn | 61 | 2023 | 25470 | 1.680 |
Why?
|
HIV Seropositivity | 10 | 2023 | 966 | 1.630 |
Why?
|
Benzoxazines | 6 | 2023 | 306 | 1.570 |
Why?
|
Nevirapine | 12 | 2023 | 273 | 1.520 |
Why?
|
RNA, Viral | 12 | 2021 | 2907 | 1.460 |
Why?
|
Pregnancy Complications | 5 | 2023 | 2867 | 1.310 |
Why?
|
Viral Load | 30 | 2023 | 3299 | 1.200 |
Why?
|
Milk, Human | 7 | 2012 | 490 | 1.200 |
Why?
|
Infant | 60 | 2023 | 34923 | 1.190 |
Why?
|
Zidovudine | 16 | 2023 | 623 | 1.150 |
Why?
|
Neural Tube Defects | 2 | 2019 | 253 | 1.150 |
Why?
|
HIV | 10 | 2022 | 1607 | 0.990 |
Why?
|
Infant, Small for Gestational Age | 5 | 2021 | 438 | 0.980 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2020 | 624 | 0.930 |
Why?
|
Hypertension, Pregnancy-Induced | 2 | 2021 | 482 | 0.910 |
Why?
|
Maternal-Fetal Exchange | 4 | 2020 | 454 | 0.890 |
Why?
|
Circumcision, Male | 7 | 2020 | 139 | 0.880 |
Why?
|
Dideoxynucleosides | 2 | 2012 | 124 | 0.840 |
Why?
|
Leukocytes, Mononuclear | 6 | 2023 | 1820 | 0.830 |
Why?
|
Infant Formula | 6 | 2021 | 200 | 0.830 |
Why?
|
Prenatal Exposure Delayed Effects | 7 | 2019 | 2393 | 0.800 |
Why?
|
CD4 Lymphocyte Count | 12 | 2023 | 2602 | 0.780 |
Why?
|
Oxazines | 5 | 2021 | 302 | 0.780 |
Why?
|
Fetal Growth Retardation | 2 | 2015 | 570 | 0.770 |
Why?
|
Polydactyly | 1 | 2021 | 57 | 0.760 |
Why?
|
Lamivudine | 5 | 2023 | 342 | 0.750 |
Why?
|
Female | 116 | 2023 | 378853 | 0.750 |
Why?
|
Rotavirus Vaccines | 1 | 2020 | 64 | 0.730 |
Why?
|
HIV Integrase Inhibitors | 2 | 2019 | 144 | 0.710 |
Why?
|
Pneumonia, Pneumococcal | 1 | 2020 | 126 | 0.710 |
Why?
|
Vaccines, Conjugate | 1 | 2020 | 332 | 0.680 |
Why?
|
Drug Resistance, Viral | 8 | 2023 | 829 | 0.680 |
Why?
|
Humans | 165 | 2023 | 739398 | 0.670 |
Why?
|
Quarantine | 1 | 2020 | 169 | 0.650 |
Why?
|
Alkynes | 5 | 2020 | 310 | 0.650 |
Why?
|
Pyridones | 5 | 2021 | 707 | 0.630 |
Why?
|
Adult | 82 | 2023 | 213394 | 0.620 |
Why?
|
Cyclopropanes | 5 | 2020 | 421 | 0.620 |
Why?
|
Diarrhea | 3 | 2020 | 1342 | 0.620 |
Why?
|
DNA, Viral | 8 | 2023 | 2223 | 0.610 |
Why?
|
Gestational Age | 3 | 2021 | 3486 | 0.600 |
Why?
|
Proviruses | 7 | 2023 | 316 | 0.600 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 391 | 0.580 |
Why?
|
Syphilis | 1 | 2019 | 225 | 0.580 |
Why?
|
Enzyme Assays | 1 | 2017 | 111 | 0.570 |
Why?
|
Early Diagnosis | 2 | 2019 | 1186 | 0.540 |
Why?
|
Postpartum Period | 5 | 2020 | 1070 | 0.540 |
Why?
|
Antimalarials | 1 | 2022 | 913 | 0.530 |
Why?
|
Lactation | 3 | 2012 | 410 | 0.530 |
Why?
|
Child Development | 6 | 2019 | 2213 | 0.520 |
Why?
|
Viremia | 5 | 2023 | 733 | 0.520 |
Why?
|
HIV Protease Inhibitors | 3 | 2018 | 435 | 0.520 |
Why?
|
Child Mortality | 2 | 2018 | 191 | 0.520 |
Why?
|
Causality | 2 | 2019 | 1262 | 0.520 |
Why?
|
Congenital Abnormalities | 2 | 2019 | 708 | 0.510 |
Why?
|
Anti-Bacterial Agents | 5 | 2023 | 7136 | 0.490 |
Why?
|
Hospitalization | 8 | 2021 | 10208 | 0.490 |
Why?
|
Antibodies, Neutralizing | 6 | 2023 | 1957 | 0.480 |
Why?
|
Hepatitis B | 4 | 2023 | 688 | 0.460 |
Why?
|
Hospitals, District | 3 | 2019 | 105 | 0.460 |
Why?
|
Developmental Disabilities | 3 | 2019 | 1445 | 0.460 |
Why?
|
Travel | 1 | 2019 | 787 | 0.450 |
Why?
|
Mothers | 5 | 2020 | 2143 | 0.450 |
Why?
|
Malaria | 1 | 2022 | 1234 | 0.430 |
Why?
|
Mastitis | 1 | 2012 | 41 | 0.430 |
Why?
|
Piperazines | 5 | 2021 | 2480 | 0.420 |
Why?
|
Drug Therapy, Combination | 7 | 2021 | 6478 | 0.410 |
Why?
|
HIV Antibodies | 5 | 2023 | 1309 | 0.410 |
Why?
|
Placental Insufficiency | 1 | 2012 | 51 | 0.410 |
Why?
|
Live Birth | 1 | 2015 | 512 | 0.400 |
Why?
|
HIV Seronegativity | 1 | 2011 | 209 | 0.380 |
Why?
|
Prevalence | 12 | 2023 | 15153 | 0.380 |
Why?
|
Drug Resistance, Bacterial | 1 | 2017 | 1031 | 0.360 |
Why?
|
Child | 25 | 2023 | 77033 | 0.360 |
Why?
|
Botulism | 3 | 1999 | 22 | 0.360 |
Why?
|
Progesterone | 1 | 2014 | 772 | 0.360 |
Why?
|
Weaning | 1 | 2010 | 105 | 0.360 |
Why?
|
Young Adult | 23 | 2022 | 56255 | 0.350 |
Why?
|
Immune Evasion | 3 | 2022 | 358 | 0.350 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 388 | 0.340 |
Why?
|
Hepatitis B virus | 4 | 2023 | 510 | 0.340 |
Why?
|
Pregnant Women | 3 | 2023 | 558 | 0.340 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1175 | 0.330 |
Why?
|
Fetal Development | 1 | 2014 | 763 | 0.330 |
Why?
|
HLA Antigens | 4 | 2015 | 1382 | 0.320 |
Why?
|
Birth Weight | 3 | 2023 | 2062 | 0.320 |
Why?
|
Health Services Research | 2 | 2019 | 1832 | 0.310 |
Why?
|
HLA-B Antigens | 4 | 2014 | 352 | 0.300 |
Why?
|
Population Surveillance | 7 | 2019 | 2629 | 0.300 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2013 | 773 | 0.300 |
Why?
|
Hepatitis B Antibodies | 3 | 2023 | 158 | 0.290 |
Why?
|
Disease Outbreaks | 6 | 2002 | 1779 | 0.290 |
Why?
|
Hepatitis B Surface Antigens | 3 | 2023 | 305 | 0.280 |
Why?
|
Child, Preschool | 17 | 2022 | 40802 | 0.270 |
Why?
|
Selection Bias | 2 | 2019 | 370 | 0.260 |
Why?
|
Neutropenia | 4 | 2017 | 888 | 0.260 |
Why?
|
Morbidity | 3 | 2021 | 1763 | 0.260 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1327 | 0.250 |
Why?
|
Survival Analysis | 3 | 2017 | 10247 | 0.250 |
Why?
|
Health Services Accessibility | 2 | 2019 | 5128 | 0.250 |
Why?
|
Hepatitis B e Antigens | 3 | 2023 | 133 | 0.250 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 4546 | 0.240 |
Why?
|
Hospital Mortality | 2 | 2019 | 5305 | 0.240 |
Why?
|
Prospective Studies | 14 | 2023 | 53037 | 0.240 |
Why?
|
Mutation, Missense | 1 | 2013 | 2552 | 0.240 |
Why?
|
Vitamin A | 2 | 2017 | 613 | 0.240 |
Why?
|
AIDS Serodiagnosis | 2 | 2020 | 202 | 0.230 |
Why?
|
Risk Factors | 19 | 2020 | 71974 | 0.230 |
Why?
|
Pre-Eclampsia | 1 | 2013 | 1194 | 0.230 |
Why?
|
Wolves | 1 | 2023 | 9 | 0.230 |
Why?
|
Parturition | 2 | 2019 | 431 | 0.230 |
Why?
|
Male | 45 | 2023 | 349022 | 0.220 |
Why?
|
Cytomegalovirus Infections | 2 | 2020 | 808 | 0.220 |
Why?
|
Infant Food | 1 | 2003 | 140 | 0.220 |
Why?
|
Immunity, Cellular | 3 | 2021 | 1603 | 0.220 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3248 | 0.210 |
Why?
|
Disease Reservoirs | 2 | 2019 | 131 | 0.210 |
Why?
|
Dog Diseases | 1 | 2023 | 136 | 0.210 |
Why?
|
Cohort Studies | 18 | 2022 | 40389 | 0.210 |
Why?
|
Salmonella | 2 | 2001 | 128 | 0.210 |
Why?
|
Infant Nutritional Physiological Phenomena | 2 | 2016 | 344 | 0.200 |
Why?
|
Infant Care | 1 | 2003 | 184 | 0.200 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2013 | 877 | 0.200 |
Why?
|
Hypertension | 2 | 2012 | 8431 | 0.200 |
Why?
|
Adolescent | 22 | 2023 | 85405 | 0.200 |
Why?
|
Chloroquine | 1 | 2022 | 280 | 0.200 |
Why?
|
RNA | 4 | 2023 | 2723 | 0.200 |
Why?
|
Genotype | 8 | 2023 | 12951 | 0.190 |
Why?
|
Vitamin D | 1 | 2014 | 3197 | 0.190 |
Why?
|
Teratogens | 1 | 2021 | 113 | 0.190 |
Why?
|
Gram-Negative Bacteria | 2 | 2003 | 270 | 0.190 |
Why?
|
Vitamin A Deficiency | 2 | 2017 | 101 | 0.180 |
Why?
|
Toes | 1 | 2021 | 208 | 0.180 |
Why?
|
Maternal Mortality | 1 | 2022 | 312 | 0.180 |
Why?
|
Communicable Disease Control | 3 | 2020 | 853 | 0.180 |
Why?
|
Case-Control Studies | 7 | 2021 | 21694 | 0.180 |
Why?
|
Tetanus Toxoid | 1 | 2020 | 193 | 0.180 |
Why?
|
Food Handling | 2 | 1999 | 144 | 0.170 |
Why?
|
Salmonella Food Poisoning | 1 | 1999 | 15 | 0.170 |
Why?
|
Antibodies, Viral | 2 | 2021 | 3151 | 0.170 |
Why?
|
Adenine | 2 | 2023 | 940 | 0.170 |
Why?
|
Micronutrients | 1 | 2022 | 364 | 0.170 |
Why?
|
Hepatitis B Vaccines | 1 | 2020 | 194 | 0.170 |
Why?
|
Ostreidae | 1 | 1998 | 3 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2016 | 4424 | 0.170 |
Why?
|
Meat | 2 | 1999 | 594 | 0.170 |
Why?
|
Paternal Exposure | 1 | 2019 | 89 | 0.170 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 127 | 0.170 |
Why?
|
Anthropometry | 2 | 2016 | 1344 | 0.170 |
Why?
|
Vibrio | 1 | 1998 | 39 | 0.160 |
Why?
|
Vibrio Infections | 1 | 1998 | 33 | 0.160 |
Why?
|
Mortality | 1 | 2010 | 2851 | 0.160 |
Why?
|
Obstetric Labor, Premature | 1 | 2020 | 282 | 0.160 |
Why?
|
Neonatal Screening | 2 | 2020 | 591 | 0.160 |
Why?
|
Feces | 4 | 2017 | 1389 | 0.160 |
Why?
|
Water Microbiology | 1 | 1999 | 117 | 0.160 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2020 | 136 | 0.160 |
Why?
|
Drug Resistance, Microbial | 2 | 2017 | 860 | 0.160 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7709 | 0.160 |
Why?
|
Fingers | 1 | 2021 | 511 | 0.160 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.150 |
Why?
|
CD4-Positive T-Lymphocytes | 6 | 2023 | 4374 | 0.150 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 261 | 0.150 |
Why?
|
Patient Compliance | 2 | 2010 | 2679 | 0.150 |
Why?
|
Double-Blind Method | 5 | 2021 | 11985 | 0.150 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 3 | 2013 | 221 | 0.150 |
Why?
|
Cytokines | 1 | 2012 | 7298 | 0.150 |
Why?
|
Infant, Low Birth Weight | 2 | 2018 | 848 | 0.150 |
Why?
|
Inpatients | 2 | 2019 | 2478 | 0.140 |
Why?
|
Fetal Death | 1 | 2018 | 446 | 0.140 |
Why?
|
Motor Skills | 1 | 2019 | 520 | 0.140 |
Why?
|
Diarrhea, Infantile | 1 | 2016 | 109 | 0.140 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 2 | 2013 | 151 | 0.140 |
Why?
|
Cervix Uteri | 1 | 2020 | 591 | 0.140 |
Why?
|
Restaurants | 1 | 1999 | 236 | 0.140 |
Why?
|
Immunoglobulin M | 3 | 2023 | 1537 | 0.130 |
Why?
|
Polymerase Chain Reaction | 3 | 2020 | 6174 | 0.130 |
Why?
|
Immunity, Innate | 3 | 2022 | 2950 | 0.130 |
Why?
|
Folic Acid | 1 | 2022 | 1297 | 0.130 |
Why?
|
Labor, Induced | 1 | 2016 | 146 | 0.130 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4935 | 0.130 |
Why?
|
Escherichia coli | 2 | 2017 | 4220 | 0.130 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 12328 | 0.130 |
Why?
|
Drug Combinations | 1 | 2020 | 1959 | 0.130 |
Why?
|
Nervous System | 1 | 2018 | 557 | 0.130 |
Why?
|
Cross-Sectional Studies | 9 | 2023 | 24714 | 0.120 |
Why?
|
Vascular Diseases | 1 | 2023 | 1152 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 789 | 0.120 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2017 | 320 | 0.120 |
Why?
|
HLA-B7 Antigen | 1 | 2013 | 48 | 0.120 |
Why?
|
Adaptation, Biological | 1 | 2014 | 150 | 0.120 |
Why?
|
Dietary Supplements | 3 | 2022 | 3279 | 0.120 |
Why?
|
Iron | 1 | 2022 | 1776 | 0.120 |
Why?
|
Withholding Treatment | 2 | 2019 | 596 | 0.120 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14740 | 0.110 |
Why?
|
Rural Population | 6 | 2019 | 2181 | 0.110 |
Why?
|
HLA-B35 Antigen | 1 | 2012 | 8 | 0.110 |
Why?
|
Immunologic Memory | 1 | 2020 | 1348 | 0.110 |
Why?
|
Respiratory System | 1 | 2016 | 553 | 0.110 |
Why?
|
Africa South of the Sahara | 2 | 2020 | 727 | 0.110 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2006 | 231 | 0.110 |
Why?
|
Anemia | 2 | 2013 | 1498 | 0.110 |
Why?
|
Seasons | 2 | 2014 | 1486 | 0.110 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2021 | 2241 | 0.110 |
Why?
|
Prenatal Care | 1 | 2020 | 1087 | 0.110 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2019 | 806 | 0.110 |
Why?
|
Phylogeny | 4 | 2023 | 2789 | 0.110 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 631 | 0.110 |
Why?
|
Selection, Genetic | 2 | 2014 | 915 | 0.110 |
Why?
|
Heterosexuality | 1 | 2014 | 272 | 0.110 |
Why?
|
Shock, Septic | 1 | 2019 | 764 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9812 | 0.110 |
Why?
|
Cholera | 1 | 1999 | 780 | 0.100 |
Why?
|
Birth Certificates | 1 | 2011 | 67 | 0.100 |
Why?
|
Pregnancy Proteins | 1 | 2013 | 229 | 0.100 |
Why?
|
Mass Screening | 3 | 2020 | 5265 | 0.100 |
Why?
|
Kenya | 4 | 2006 | 678 | 0.100 |
Why?
|
Gene Products, gag | 1 | 2012 | 337 | 0.100 |
Why?
|
Fetus | 1 | 2019 | 1877 | 0.100 |
Why?
|
Evolution, Molecular | 3 | 2016 | 1936 | 0.100 |
Why?
|
Antihypertensive Agents | 1 | 2021 | 2039 | 0.100 |
Why?
|
Vitamins | 2 | 2017 | 1602 | 0.100 |
Why?
|
Equipment and Supplies | 1 | 2014 | 280 | 0.100 |
Why?
|
Mutation | 9 | 2023 | 29658 | 0.100 |
Why?
|
Middle Aged | 17 | 2021 | 212863 | 0.100 |
Why?
|
Disaster Planning | 1 | 1997 | 550 | 0.100 |
Why?
|
HLA-A Antigens | 1 | 2011 | 228 | 0.090 |
Why?
|
Virus Replication | 2 | 2016 | 2529 | 0.090 |
Why?
|
Logistic Models | 4 | 2013 | 13402 | 0.090 |
Why?
|
Retrospective Studies | 9 | 2023 | 76631 | 0.090 |
Why?
|
Molecular Sequence Data | 5 | 2014 | 18125 | 0.090 |
Why?
|
Africa, Southern | 3 | 2016 | 57 | 0.090 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4332 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 551 | 0.090 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 7726 | 0.090 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2016 | 1359 | 0.090 |
Why?
|
Adaptation, Physiological | 1 | 2016 | 1310 | 0.090 |
Why?
|
Body Height | 1 | 2016 | 1577 | 0.090 |
Why?
|
Clostridium botulinum | 2 | 1999 | 21 | 0.080 |
Why?
|
Botulinum Antitoxin | 2 | 1999 | 2 | 0.080 |
Why?
|
Placenta | 2 | 2023 | 1682 | 0.080 |
Why?
|
Regression Analysis | 2 | 2016 | 6452 | 0.080 |
Why?
|
Africa | 3 | 2018 | 666 | 0.080 |
Why?
|
Drug Utilization | 1 | 2015 | 1181 | 0.080 |
Why?
|
Alleles | 4 | 2012 | 6942 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 221 | 0.080 |
Why?
|
Follow-Up Studies | 6 | 2019 | 38942 | 0.080 |
Why?
|
Pneumonia | 2 | 2019 | 2102 | 0.080 |
Why?
|
South Africa | 3 | 2022 | 1743 | 0.080 |
Why?
|
Body Size | 1 | 2011 | 458 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2013 | 2974 | 0.080 |
Why?
|
Prenatal Diagnosis | 1 | 2015 | 1227 | 0.080 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 26 | 0.080 |
Why?
|
Chemoprevention | 1 | 2010 | 323 | 0.080 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2011 | 386 | 0.080 |
Why?
|
Cause of Death | 2 | 2019 | 3564 | 0.080 |
Why?
|
Protease Inhibitors | 1 | 2011 | 792 | 0.080 |
Why?
|
Patient Acceptance of Health Care | 3 | 2014 | 3021 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2019 | 2012 | 0.070 |
Why?
|
Haemophilus influenzae | 1 | 2007 | 171 | 0.070 |
Why?
|
Developing Countries | 1 | 2019 | 2779 | 0.070 |
Why?
|
Tuberculosis | 1 | 2019 | 1892 | 0.070 |
Why?
|
Voluntary Programs | 1 | 2006 | 45 | 0.070 |
Why?
|
Dysentery | 1 | 2006 | 12 | 0.070 |
Why?
|
Risk Assessment | 2 | 2018 | 23294 | 0.070 |
Why?
|
Antibodies, Monoclonal | 1 | 2023 | 9259 | 0.070 |
Why?
|
Biomedical Research | 1 | 2021 | 3301 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 973 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9684 | 0.070 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 4791 | 0.070 |
Why?
|
Time Factors | 6 | 2019 | 40050 | 0.070 |
Why?
|
Medication Adherence | 1 | 2017 | 2047 | 0.060 |
Why?
|
Antibody Specificity | 1 | 2007 | 1096 | 0.060 |
Why?
|
Communication | 1 | 2019 | 3722 | 0.060 |
Why?
|
Body Weight | 1 | 2016 | 4660 | 0.060 |
Why?
|
Postnatal Care | 1 | 2006 | 233 | 0.060 |
Why?
|
Epidemics | 1 | 2010 | 520 | 0.060 |
Why?
|
Helicobacter pylori | 1 | 2007 | 379 | 0.060 |
Why?
|
Hepatitis Delta Virus | 1 | 2023 | 18 | 0.060 |
Why?
|
Environmental Exposure | 1 | 2018 | 4220 | 0.060 |
Why?
|
Immunoglobulin A | 1 | 2007 | 989 | 0.060 |
Why?
|
Vibrio cholerae | 2 | 2001 | 806 | 0.060 |
Why?
|
Clinical Competence | 1 | 2019 | 4671 | 0.060 |
Why?
|
Sex Factors | 2 | 2014 | 10398 | 0.060 |
Why?
|
Mozambique | 1 | 2022 | 54 | 0.060 |
Why?
|
HIV-2 | 1 | 2023 | 171 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2020 | 12237 | 0.060 |
Why?
|
Immunologic Factors | 1 | 2012 | 1571 | 0.060 |
Why?
|
Aged | 11 | 2023 | 162698 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7274 | 0.050 |
Why?
|
Medicago sativa | 1 | 2001 | 17 | 0.050 |
Why?
|
Epitopes | 2 | 2023 | 2558 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2133 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6686 | 0.050 |
Why?
|
Models, Theoretical | 1 | 2014 | 3609 | 0.050 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2006 | 563 | 0.050 |
Why?
|
Streptococcus pneumoniae | 1 | 2007 | 714 | 0.050 |
Why?
|
Escherichia coli O157 | 1 | 2001 | 52 | 0.050 |
Why?
|
Food Microbiology | 1 | 2001 | 77 | 0.050 |
Why?
|
Rural Health | 1 | 2003 | 304 | 0.050 |
Why?
|
Campylobacter | 1 | 2001 | 59 | 0.050 |
Why?
|
Antibodies, Bacterial | 1 | 2007 | 1465 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15511 | 0.050 |
Why?
|
Shigella | 1 | 2001 | 75 | 0.050 |
Why?
|
Leukocytes | 1 | 2009 | 2035 | 0.050 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2023 | 363 | 0.050 |
Why?
|
E-Selectin | 1 | 2023 | 577 | 0.050 |
Why?
|
Urban Health | 1 | 2003 | 547 | 0.050 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2023 | 705 | 0.050 |
Why?
|
Immunity, Maternally-Acquired | 1 | 2020 | 117 | 0.040 |
Why?
|
Cervical Length Measurement | 1 | 2020 | 41 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 13872 | 0.040 |
Why?
|
Papillomavirus Infections | 1 | 2011 | 1585 | 0.040 |
Why?
|
South Dakota | 1 | 1999 | 31 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2881 | 0.040 |
Why?
|
Clinical Audit | 1 | 2019 | 31 | 0.040 |
Why?
|
Fresh Water | 1 | 1999 | 83 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1153 | 0.040 |
Why?
|
Patients' Rooms | 1 | 2019 | 63 | 0.040 |
Why?
|
Fertilization | 1 | 2020 | 196 | 0.040 |
Why?
|
Shellfish | 1 | 1998 | 38 | 0.040 |
Why?
|
North America | 1 | 2022 | 1249 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 578 | 0.040 |
Why?
|
Counseling | 1 | 2006 | 1526 | 0.040 |
Why?
|
Nitriles | 1 | 2023 | 946 | 0.040 |
Why?
|
Language Development | 1 | 2019 | 187 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 3908 | 0.040 |
Why?
|
Antitoxins | 1 | 1998 | 84 | 0.040 |
Why?
|
Seawater | 1 | 1998 | 121 | 0.040 |
Why?
|
Dogs | 1 | 2023 | 3915 | 0.040 |
Why?
|
Linear Models | 2 | 2020 | 5948 | 0.040 |
Why?
|
Serologic Tests | 1 | 2020 | 373 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4743 | 0.040 |
Why?
|
Escherichia coli Infections | 1 | 2001 | 529 | 0.040 |
Why?
|
Telemedicine | 1 | 2015 | 2844 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2019 | 456 | 0.040 |
Why?
|
Treatment Outcome | 4 | 2014 | 62693 | 0.040 |
Why?
|
BCG Vaccine | 1 | 2020 | 362 | 0.040 |
Why?
|
Weather | 1 | 1998 | 228 | 0.040 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 732 | 0.040 |
Why?
|
Linkage Disequilibrium | 2 | 2012 | 1992 | 0.040 |
Why?
|
Sexually Transmitted Diseases | 1 | 2002 | 616 | 0.040 |
Why?
|
Sentinel Surveillance | 1 | 1999 | 291 | 0.040 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1591 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2021 | 595 | 0.040 |
Why?
|
Asia | 1 | 2018 | 604 | 0.040 |
Why?
|
Tachycardia | 1 | 2019 | 621 | 0.040 |
Why?
|
Drug Resistance | 1 | 2022 | 1610 | 0.030 |
Why?
|
Pulmonary Edema | 1 | 2019 | 415 | 0.030 |
Why?
|
Base Sequence | 2 | 2019 | 12804 | 0.030 |
Why?
|
British Columbia | 1 | 2016 | 237 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2003 | 1127 | 0.030 |
Why?
|
Europe | 1 | 2022 | 3331 | 0.030 |
Why?
|
Immunoglobulin G | 1 | 2007 | 4522 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2019 | 591 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1279 | 0.030 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2014 | 65 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2020 | 13880 | 0.030 |
Why?
|
Incidence | 3 | 2019 | 20913 | 0.030 |
Why?
|
Phlebotomy | 1 | 2015 | 142 | 0.030 |
Why?
|
Consensus Sequence | 1 | 2014 | 378 | 0.030 |
Why?
|
Models, Immunological | 1 | 2016 | 527 | 0.030 |
Why?
|
Seroepidemiologic Studies | 1 | 2014 | 401 | 0.030 |
Why?
|
United States | 4 | 2011 | 69573 | 0.030 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 1689 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2020 | 1883 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2002 | 2040 | 0.030 |
Why?
|
Disease Progression | 3 | 2015 | 13237 | 0.030 |
Why?
|
Hot Temperature | 1 | 1999 | 1358 | 0.030 |
Why?
|
Hypotension | 1 | 2019 | 881 | 0.030 |
Why?
|
Tanzania | 1 | 2016 | 1303 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2012 | 131 | 0.030 |
Why?
|
Animals | 4 | 2023 | 168368 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2019 | 914 | 0.030 |
Why?
|
Amino Acid Sequence | 2 | 2014 | 13816 | 0.030 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 28 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2019 | 1054 | 0.030 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 39 | 0.030 |
Why?
|
Models, Molecular | 1 | 2022 | 5460 | 0.020 |
Why?
|
Pyrimidines | 1 | 2023 | 2918 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2020 | 3193 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2012 | 5959 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2012 | 6370 | 0.020 |
Why?
|
Emergencies | 1 | 1997 | 1152 | 0.020 |
Why?
|
Virulence | 1 | 2014 | 1321 | 0.020 |
Why?
|
Herpes Genitalis | 1 | 2011 | 141 | 0.020 |
Why?
|
Mexico | 1 | 2012 | 683 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2019 | 1197 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2011 | 185 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2583 | 0.020 |
Why?
|
Pilot Projects | 1 | 2003 | 8275 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2013 | 1203 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2011 | 257 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2971 | 0.020 |
Why?
|
AIDS Vaccines | 1 | 2016 | 924 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2019 | 57650 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 2 | 2006 | 1866 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 225 | 0.020 |
Why?
|
Immunization | 1 | 2013 | 1255 | 0.020 |
Why?
|
Point Mutation | 1 | 2014 | 1626 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2014 | 554 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 928 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2013 | 629 | 0.020 |
Why?
|
World Health Organization | 1 | 2014 | 1321 | 0.020 |
Why?
|
Japan | 1 | 2012 | 1348 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2011 | 479 | 0.020 |
Why?
|
HIV Antigens | 1 | 2009 | 343 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3526 | 0.020 |
Why?
|
Patient Care Team | 1 | 2019 | 2527 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1407 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 1998 | 2560 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2016 | 2517 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 2008 | 418 | 0.020 |
Why?
|
Maternal-Child Health Centers | 1 | 2006 | 40 | 0.020 |
Why?
|
HIV Seroprevalence | 1 | 2006 | 87 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2008 | 591 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 780 | 0.020 |
Why?
|
Gene Frequency | 1 | 2012 | 3585 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4182 | 0.020 |
Why?
|
Bacteria | 1 | 2016 | 2106 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1650 | 0.020 |
Why?
|
Marital Status | 1 | 2006 | 435 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2014 | 1530 | 0.020 |
Why?
|
Databases, Factual | 1 | 2019 | 7690 | 0.020 |
Why?
|
Pregnancy Trimester, Third | 1 | 2007 | 568 | 0.020 |
Why?
|
Genetic Variation | 1 | 2019 | 6539 | 0.020 |
Why?
|
Occupations | 1 | 2006 | 517 | 0.020 |
Why?
|
Public Health Practice | 1 | 2006 | 217 | 0.010 |
Why?
|
Maternal Age | 1 | 2006 | 803 | 0.010 |
Why?
|
Labor, Obstetric | 1 | 2007 | 337 | 0.010 |
Why?
|
Internationality | 1 | 2009 | 1004 | 0.010 |
Why?
|
Hemoglobins | 1 | 2008 | 1529 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10142 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16301 | 0.010 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 1 | 2001 | 144 | 0.010 |
Why?
|
Virginia | 1 | 2001 | 121 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2014 | 3571 | 0.010 |
Why?
|
Seeds | 1 | 2001 | 105 | 0.010 |
Why?
|
Culture Media | 1 | 2003 | 902 | 0.010 |
Why?
|
Michigan | 1 | 2001 | 349 | 0.010 |
Why?
|
Treatment Failure | 1 | 2007 | 2614 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5113 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2006 | 2448 | 0.010 |
Why?
|
Gene Expression | 1 | 2012 | 7788 | 0.010 |
Why?
|
Educational Status | 1 | 2006 | 2514 | 0.010 |
Why?
|
Argentina | 1 | 1999 | 232 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2006 | 1409 | 0.010 |
Why?
|
Health Promotion | 1 | 2010 | 2187 | 0.010 |
Why?
|
Vagina | 1 | 2003 | 822 | 0.010 |
Why?
|
Food Contamination | 1 | 1999 | 187 | 0.010 |
Why?
|
Research Design | 1 | 2012 | 5959 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2001 | 1467 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6516 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2006 | 6871 | 0.010 |
Why?
|
Pharmaceutical Preparations | 1 | 1999 | 1066 | 0.010 |
Why?
|